Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | PRCP | P42785 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28206529 | 0.85 | KMT2A (0.74) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL24724688 | 0.85 | KMT2A (0.74) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL10644709 | 0.83 | KMT2A (0.56) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL22728762 | 0.81 | GID4 (1.00) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL29498352 | 0.81 | GID4 (1.00) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL3065108 | 0.81 | GID4 (1.00) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL22728765 | 0.80 | GID4 (0.63) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL2792861 | 0.80 | GID4 (0.63) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL2796297 | 0.80 | GID4 (0.63) | GID4KMT2AMEN1PRCPGAA | |
| SCHEMBL15033501 | 0.80 | GID4 (0.72) | GID4KMT2AMEN1PRCPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235082-A1 | CATALYSTS | THE UNIVERSITY OF WARWICK (GB) | 2022-07-28 | — | — | US | disclosed |
| WO-2020240178-A1 | CATALYSTS | GoldenKeys High-tech Materials Co., Ltd. (CN) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235082-A1 | CATALYSTS | TST, TCP1, CCT3 | GID4 3130/4885KMT2A 3433/4885MEN1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.